Jaundice

Definition and Overview

Jaundice, also known as icterus, is a clinical sign characterized by yellow pigmentation of the skin, sclerae (whites of the eyes), and mucous membranes due to elevated levels of bilirubin in the blood (hyperbilirubinemia). It becomes clinically detectable when the serum bilirubin level exceeds approximately 40-50 µmol/L (2-3 mg/dL). It is not a disease itself but a symptom of an underlying disorder in bilirubin metabolism, transport, or excretion.

Epidemiology and Risk Factors

The epidemiology of jaundice is entirely dependent on its underlying cause. However, some patterns are important:

• Age: Neonatal jaundice is extremely common (affecting ~60% of term infants). In adults, the causes shift. Malignant biliary obstruction (e.g., pancreatic cancer, cholangiocarcinoma) is more common in the elderly, while gallstone disease peaks in middle age.
• Geography/Hong Kong Context: Certain etiologies have a higher prevalence in Asia and Hong Kong:
  • Hepatitis B Virus (HBV) Infection: Hong Kong has an intermediate endemicity. Chronic HBV is a leading cause of cirrhosis and hepatocellular carcinoma (HCC), both of which can present with jaundice.
  • Recurrent Pyogenic Cholangitis (RPC): Known historically as "Hong Kong disease." Associated with intrahepatic pigment stone formation and parasitic infections (e.g., Clonorchis sinensis from raw freshwater fish).
  • Cholangiocarcinoma: Higher incidence in regions with endemic liver fluke infestation and RPC.
• General Risk Factors:
  • Gallstones: Female gender, obesity, rapid weight loss, pregnancy (the "4 F's" - Female, Fat, Forty, Fertile - is an outdated but classic mnemonic).
  • Alcoholic Liver Disease: Chronic heavy alcohol use.
  • Medications: Many drugs can cause hepatocellular injury or cholestasis (e.g., antibiotics, NSAIDs, anticonvulsants).
  • Genetic Disorders: Gilbert's syndrome (very common, ~5-10% of population), Crigler-Najjar, Dubin-Johnson syndromes.

Anatomy and Function of the Biliary System

Understanding the biliary tree's anatomy is crucial for localizing the cause of obstructive jaundice.

Key Anatomical Points:

• Bile Production: Hepatocytes continuously produce bile, which is modified by ductal cells.
• Gallbladder Function: Stores and concentrates bile by absorbing water and electrolytes. Contracts in response to cholecystokinin (CCK) after a meal, ejecting bile.
• Sphincter of Oddi: A smooth muscle valve that controls the flow of bile and pancreatic juice into the duodenum and prevents duodenal contents from refluxing back.
• Blood Supply: The liver has a dual supply: the hepatic artery (25% of flow, 50% of oxygen) and the portal vein (75% of flow, 50% of oxygen). The bile ducts are supplied by the hepatic artery, making them vulnerable to ischemic injury.

Bilirubin Metabolism (The "Lifecycle" of a Red Blood Cell)

To understand jaundice, you must know bilirubin metabolism inside out. This is a classic exam topic.

Step 1: Production (Pre-hepatic Phase)

• Source: 80-85% comes from the breakdown of senescent red blood cells (RBCs) in the spleen, liver, and bone marrow. The heme portion of hemoglobin is the precursor.
• Process: Macrophages break down heme into iron (recycled), carbon monoxide (exhaled), and biliverdin (green pigment). Biliverdin is rapidly converted to unconjugated bilirubin (UCB).
• Characteristics of UCB: It is lipid-soluble, insoluble in water, and tightly bound to albumin in the blood. It cannot be excreted in urine.

Step 2: Hepatic Uptake & Conjugation (Hepatic Phase)

• Uptake: UCB-albumin complex travels to the liver. UCB dissociates and is taken up by hepatocytes via specific transporters.
• Conjugation: Inside the hepatocyte, UCB is conjugated with glucuronic acid by the enzyme UDP-glucuronosyltransferase (UGT1A1) to form conjugated bilirubin (CB).
• Characteristics of CB: It is water-soluble, non-toxic, and can be excreted.

Step 3: Excretion & Enterohepatic Circulation (Post-hepatic Phase)

• Excretion: CB is actively secreted into bile canaliculi and flows down the biliary tree into the duodenum.
• Intestinal Fate: In the colon, bacteria deconjugate CB and convert it into urobilinogen.
  • Most urobilinogen is oxidized to stercobilin (brown pigment) and excreted in stool.
  • About 20% is reabsorbed into the portal circulation (enterohepatic circulation).
• Renal Fate: The reabsorbed urobilinogen is mostly re-excreted by the liver. A small amount (~2%) is excreted by the kidneys, giving urine its yellow color.

Etiology and Pathophysiology

Jaundice is classified based on which step in bilirubin metabolism is disrupted. The three main categories are pre-hepatic, hepatic (hepatocellular), and post-hepatic (obstructive/cholestatic).

1. Pre-hepatic Jaundice (Unconjugated Hyperbilirubinemia)

• Pathophysiology: Excessive production of bilirubin overwhelms the liver's normal capacity to conjugate and excrete it. The liver is normal but cannot keep up.
• Key Etiologies:
  • Hemolysis: Breakdown of RBCs. Causes include autoimmune hemolytic anemia, G6PD deficiency, sickle cell crisis, malaria, prosthetic heart valves.
  • Ineffective Erythropoiesis: Seen in megaloblastic anemias (B12/folate deficiency), thalassemia.
  • Large Hematoma Resorption: After major trauma or surgery.
• Hong Kong Relevance: G6PD deficiency is relatively common in Southern Chinese males.

2. Hepatic (Hepatocellular) Jaundice

• Pathophysiology: Dysfunction of the hepatocytes themselves. This impairs all three hepatic steps: uptake, conjugation, and excretion. Therefore, you see a mixed picture with elevations of both unconjugated and conjugated bilirubin, but often with a predominance of conjugated because excretion is the rate-limiting step.
• Key Etiologies:
  • Viral Hepatitis: Hepatitis A, B, C, D, E. HBV is a major cause in HK.
  • Alcoholic Liver Disease: From fatty liver to hepatitis to cirrhosis.
  • Non-Alcoholic Fatty Liver Disease (NAFLD)/NASH: Increasingly common with the obesity epidemic.
  • Cirrhosis (any cause): End-stage of chronic liver disease. In HK, HBV is the most common cause of cirrhosis ^[1].
  • Drug-Induced Liver Injury (DILI): A huge list (e.g., paracetamol overdose, antibiotics, antituberculous drugs).
  • Autoimmune Hepatitis.
  • Genetic Disorders: Wilson's disease, hemochromatosis, alpha-1 antitrypsin deficiency.
  • Ischemic Hepatitis ("Shock Liver").

3. Post-hepatic/Obstructive Jaundice (Conjugated Hyperbilirubinemia)

• Pathophysiology: Mechanical obstruction of the biliary tree prevents the flow of conjugated bilirubin from the liver to the intestine. Pressure builds up, causing bile to "back up" into the liver and leak into the bloodstream (cholemia). Conjugated bilirubin is water-soluble and appears in the urine.
• Key Etiologies (Use Anatomical Level):
  • Intraluminal: Choledocholithiasis (CBD stone) - the most common cause of painful obstructive jaundice.
  • Mural (Wall of the duct):
    • Malignant: Cholangiocarcinoma (e.g., Klatskin tumor at the hilum), malignant stricture.
    • Benign: Primary Sclerosing Cholangitis (PSC), post-surgical stricture, Recurrent Pyogenic Cholangitis (RPC) with strictures.
  • Extramural (Compression from outside):
    • Carcinoma of the head of the pancreas - the classic cause of painless progressive obstructive jaundice.
    • Lymphadenopathy at the porta hepatis (e.g., from metastases).
    • Mirizzi syndrome: A gallstone impacted in the cystic duct compresses the CHD/CBD.

Classification of Jaundice

Beyond the pathophysiological triad, jaundice can be classified in other useful ways:

• Conjugated vs. Unconjugated: Based on lab findings (the "Direct vs. Indirect" split).
• Medical vs. Surgical: A traditional surgical perspective.
  • Medical Jaundice: Pre-hepatic and hepatic causes. Management is primarily medical.
  • Surgical Jaundice: Almost synonymous with obstructive/cholestatic jaundice, where the problem is mechanical and often requires endoscopic, radiological, or surgical intervention to relieve the blockage.
• Benign vs. Malignant Obstruction: A critical distinction in clinical practice.

Clinical Features: Symptoms and Signs

Connect every symptom and sign back to the underlying pathophysiology. This is what examiners love.

Symptoms

1. Yellow Discoloration (Icterus):
   • Pathophysiology: Deposition of bilirubin in tissues. Sclera first (due to high elastin affinity), then skin.
2. Dark Urine (Bilirubinuria or "Tea-colored"):
   • Pathophysiology: Exclusive to conjugated hyperbilirubinemia. Water-soluble conjugated bilirubin is filtered by the kidneys and colors the urine. This is a key differentiator between pre-hepatic/hepatic vs. obstructive causes.
3. Pale, Clay-Colored Acholic Stools:
   • Pathophysiology: Occurs in complete biliary obstruction. No bilirubin reaches the intestine → no formation of stercobilin (the brown pigment). Stools become pale, greasy (steatorrhea), and foul-smelling.
4. Pruritus (Itching):
   • Pathophysiology: Primarily associated with cholestasis (intra- or extra-hepatic). Bile salts, which are normally excreted in bile, accumulate in the skin and act as irritants. It is often generalized and worse at night. A hallmark of conditions like Primary Biliary Cholangitis (PBC).
5. Abdominal Pain:
   • Biliary Colic: Sudden, severe, constant RUQ/epigastric pain, often radiating to the back or right scapula. Caused by a gallstone transiently impacting in the cystic duct or CBD.
   • Constant Dull Pain: Suggestive of malignant obstruction (e.g., pancreatic cancer) or chronic inflammation.
   • Why pain? Distention of the biliary tree or gallbladder, inflammation of the capsule (liver or pancreas), or direct tumor invasion of nerves.
6. Fever & Rigors (Chills):
   • Pathophysiology: Indicates infection in the biliary tree, i.e., acute cholangitis. Biliary obstruction + bacterial overgrowth leads to systemic infection. Classic in choledocholithiasis and acute cholangitis.
7. Constitutional Symptoms (Weight Loss, Anorexia, Fatigue):
   • Pathophysiology: Common in malignancy (e.g., pancreatic cancer, cholangiocarcinoma) or advanced chronic liver disease. Weight loss can also be from malabsorption due to steatorrhea.
8. Bleeding Tendency (Easy Bruising, Epistaxis):
   • Pathophysiology: The liver synthesizes clotting factors (II, VII, IX, X). In liver failure or prolonged obstructive jaundice, synthesis is impaired. Also, obstructive jaundice causes malabsorption of fat-soluble vitamin K, which is a cofactor for the synthesis of these factors.

Signs

1. Scleral Icterus: The most sensitive and earliest sign.
2. Skin Examination:
   • Jaundice: Best seen in natural light. Check the palate.
   • Excoriations: Scratch marks from pruritus.
   • Spider Angiomas, Palmar Erythema, Dupuytren's Contracture: Signs of chronic liver disease.
3. Abdominal Examination:
   • Hepatomegaly: May be smooth and tender (e.g., congestion, hepatitis) or hard/nodular (e.g., cirrhosis, metastases).
   • Splenomegaly: Suggests portal hypertension (cirrhosis) or hemolysis.
   • Ascites: Shifting dullness. Suggests portal hypertension (e.g., cirrhosis) or peritoneal metastases.
   • Courvoisier's Sign: A palpable, non-tender gallbladder in the presence of jaundice suggests malignant obstruction of the CBD (e.g., pancreatic head cancer) rather than gallstones. Why? A gallbladder chronically inflamed from stones is fibrotic and cannot dilate. A malignancy causes an acute obstruction, distending a previously healthy, compliant gallbladder.
     • Exception: "Double impaction" - a stone in both the cystic duct (causing gallbladder mucocele/hydrops) and the CBD (causing jaundice).
   • Epigastric/RUQ Mass: Could be a distended gallbladder (Courvoisier's), a pancreatic mass, enlarged liver, or lymph nodes ^[4][5].
4. Stigmata of Chronic Liver Disease: As above, plus gynecomastia, testicular atrophy, caput medusae, fetor hepaticus.
5. Altered Mental Status: In severe cases, can indicate hepatic encephalopathy (from liver failure) or sepsis (from severe cholangitis - part of Reynolds' pentad).

References

^[1] Senior notes: felixlai.md (Liver cirrhosis) ^[2] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p22) ^[3] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p23) ^[4] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p32) ^[5] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p33)

Active Recall - Jaundice Fundamentals

1. A patient presents with yellow eyes and dark urine. Their total bilirubin is 80 µmol/L, with a direct (conjugated) fraction of 70 µmol/L. What is the most likely type of jaundice, and name one specific cause that would NOT explain these findings.

Your answer

Grade

Show mark scheme

Type: Conjugated (Obstructive or Hepatic) Hyperbilirubinemia. A cause that would NOT explain it: Pure hemolysis (e.g., G6PD deficiency), as this causes primarily unconjugated hyperbilirubinemia without bilirubinuria.

2. Explain the pathophysiological mechanism behind pale, clay-colored stools in a jaundiced patient.

Your answer

Grade

Show mark scheme

Mechanical obstruction of the biliary tree prevents conjugated bilirubin from reaching the intestine. Intestinal bacteria therefore cannot convert bilirubin into urobilinogen and subsequently stercobilin, the brown pigment that gives stool its normal color.

3. What is Courvoisier's sign, and what is the pathophysiological reason it points towards malignancy rather than gallstones?

Your answer

Grade

Show mark scheme

A palpable, non-tender gallbladder in a jaundiced patient. Reason: Chronic inflammation from gallstones causes a fibrotic, thickened, non-distensible gallbladder. A malignant obstruction (e.g., pancreatic head cancer) develops rapidly, causing back-pressure that distends a previously normal, compliant gallbladder.

4. List the three components of Charcot's triad and state the condition it is classically associated with.

Your answer

Grade

Show mark scheme

Fever, Right Upper Quadrant pain, Jaundice. It is classically associated with Acute Cholangitis.

5. Why does a patient with prolonged obstructive jaundice have an increased risk of bleeding? Provide two distinct physiological reasons.

Your answer

Grade

Show mark scheme

1. Malabsorption of fat-soluble vitamin K (due to lack of bile in the gut), which is a cofactor for hepatic synthesis of clotting factors II, VII, IX, X. 2. Impaired hepatic synthetic function if there is concomitant liver damage/cholestasis, leading to reduced production of clotting factors.

6. Describe the enterohepatic circulation of bilirubin. What happens to the urobilinogen that is reabsorbed from the intestine?

Your answer

Grade

Show mark scheme

Conjugated bilirubin is excreted in bile into the duodenum. Gut bacteria deconjugate it and convert it to urobilinogen. Most urobilinogen is oxidized to stercobilin and excreted in feces. About 20% is reabsorbed into the portal circulation. This reabsorbed urobilinogen is mostly taken up by the liver and re-excreted in bile (enterohepatic circulation). A small fraction (~2%) escapes hepatic uptake and is excreted by the kidneys, giving urine its yellow color.

Differential Diagnosis of Jaundice

The differential diagnosis of jaundice is vast, but a systematic approach based on the pathophysiological triad (pre-hepatic, hepatic, post-hepatic) is key. The clinical presentation (painful vs. painless, acute vs. chronic, presence of fever) and simple lab/imaging findings can quickly narrow the list.

The initial, most critical step is to determine if the jaundice is conjugated or unconjugated. This splits the differential in two. Remember: conjugated bilirubin is water-soluble and appears in the urine (bilirubinuria), while unconjugated bilirubin is not.

Here is a visual algorithm to guide your clinical reasoning:

1. Pre-hepatic (Unconjugated Hyperbilirubinemia)

Pathophysiology: Overproduction of bilirubin overwhelms a normal liver's conjugation capacity.

• Hemolytic Anemias: Increased RBC breakdown.
  • Intrinsic RBC defects: Hereditary spherocytosis, G6PD deficiency (common in Southern Chinese), sickle cell disease.
  • Extrinsic causes: Autoimmune hemolytic anemia, malaria, mechanical heart valves, microangiopathic hemolytic anemia (e.g., DIC).
  • Why jaundice? The liver's UGT enzyme system is saturated. Bilirubin is primarily unconjugated, so urine is NOT dark (no bilirubinuria), but urine urobilinogen is high.
• Ineffective Erythropoiesis: Premature destruction of RBC precursors in bone marrow (e.g., megaloblastic anemias from B12/folate deficiency, thalassemia).
• Large Hematoma/Bruise Resorption: Breakdown of extravasated blood releases heme.
• Gilbert's Syndrome: The most common inherited cause. Mild, chronic unconjugated hyperbilirubinemia due to reduced UGT1A1 activity (to ~30% of normal). It's benign, often triggered by fasting, illness, or stress.

2. Hepatic (Hepatocellular) Jaundice

Pathophysiology: Hepatocyte dysfunction impairs uptake, conjugation, AND excretion. Lab shows a mixed pattern (both conjugated and unconjugated bilirubin elevated, with conjugated often >50%), markedly elevated transaminases (AST/ALT), and variable elevation in ALP.

• Viral Hepatitis: Hepatitis A, B, C, D, E. Chronic Hepatitis B is a leading cause of cirrhosis and HCC in Hong Kong ^[1].
• Alcoholic Liver Disease: Spectrum from fatty liver → alcoholic hepatitis → cirrhosis. AST:ALT ratio often >2:1.
• Non-Alcoholic Fatty Liver Disease (NAFLD)/NASH: Now a leading cause of chronic liver disease worldwide, associated with metabolic syndrome.
• Drug-Induced Liver Injury (DILI): A huge list. Can be hepatocellular (e.g., paracetamol overdose, statins), cholestatic (e.g., amoxicillin-clavulanate), or mixed.
• Autoimmune Hepatitis: More common in young to middle-aged women, with positive autoantibodies (ANA, ASMA, anti-LKM1).
• Cirrhosis (any cause): End-stage liver disease. In HK, HBV is the most common cause ^[1]. Jaundice indicates decompensation.
• Genetic/Metabolic Disorders:
  • Wilson's Disease: Copper accumulation. Look for Kayser-Fleischer rings, neurological symptoms, Coombs-negative hemolytic anemia.
  • Hemochromatosis: Iron overload. Look for bronze skin diabetes, cardiomyopathy, arthropathy.
• Ischemic Hepatitis ("Shock Liver"): From profound hypotension or heart failure. AST/ALT can rise to the thousands.

3. Post-hepatic / Obstructive (Cholestatic) Jaundice

Pathophysiology: Mechanical blockage of bile flow. Lab shows a cholestatic pattern: conjugated hyperbilirubinemia, disproportionately high ALP and GGT relative to AST/ALT. The key investigation is an abdominal ultrasound to check for biliary dilation.

It is critical to classify obstructive causes by their anatomic relation to the bile duct wall and by level of obstruction, as this guides management ^[6][7].

• Intraluminal (Inside the duct):
  • Choledocholithiasis (CBD Stone): Most common cause of painful obstructive jaundice. Stone migrates from gallbladder, causing intermittent obstruction, pain (biliary colic), and risk of acute cholangitis (fever, pain, jaundice - Charcot's triad).
  • Recurrent Pyogenic Cholangitis (RPC - 'Hong Kong Disease'): Characterized by intrahepatic pigment stone formation, strictures, and recurrent bacterial infections. A key cause of obstructive jaundice in Southeast Asia ^[8].
  • Parasitic infestation (e.g., Clonorchis sinensis from raw fish, Ascaris lumbricoides).
• Mural (Abnormality of the duct wall itself):
  • Cholangiocarcinoma: Malignancy of the bile ducts. Perihilar (Klatskin tumor) is the most common type. Why painless? It's a slow-growing, infiltrative tumor that doesn't cause acute distention.
  • Primary Sclerosing Cholangitis (PSC): Idiopathic inflammation and fibrosis causing multifocal strictures of intra- and extra-hepatic ducts. Strongly associated with Ulcerative Colitis. Presents with pruritus, jaundice, and episodes of cholangitis ^[9].
  • Malignant Stricture (e.g., from metastatic lymph nodes).
  • Benign Stricture (e.g., post-surgical, post-traumatic, chronic pancreatitis).
• Extramural (Compression from outside the duct):
  • Carcinoma of the Head of the Pancreas: The classic cause of painless, progressive obstructive jaundice in the elderly. The tumor compresses the intrapancreatic portion of the CBD. Courvoisier's sign (palpable gallbladder) is a classic finding ^[10].
  • Periampullary Carcinoma: Tumors arising from the ampulla of Vater, duodenal mucosa, or distal CBD. Can also cause painless jaundice.
  • Lymphadenopathy at the porta hepatis (from metastases, lymphoma, TB).
  • Mirizzi Syndrome: Impacted stone in the cystic duct or Hartmann's pouch causes extrinsic inflammation and compression of the common hepatic duct, leading to jaundice and cholangitis. It is an exception to Courvoisier's law (can cause jaundice with a palpable gallbladder due to associated acute cholecystitis/mucocele) ^[11].
  • Pancreatic Pseudocyst / Chronic Pancreatitis causing fibrosis and compression.

4. Special Considerations & High-Yield Distinctions

• Pediatric Jaundice: Must differentiate physiological from pathological. Causes include biliary atresia, neonatal hepatitis, metabolic disorders, and hemolytic disease of the newborn.
• Post-operative Jaundice: Consider: 1) Pre-hepatic (hemolysis from transfusion), 2) Hepatic (drugs like anesthetic agents, sepsis, hypotension-induced ischemia), 3) Post-hepatic (iatrogenic bile duct injury) ^[12].
• Hepatocellular Carcinoma (HCC): Can present with jaundice via several mechanisms: 1) Decompensation of underlying cirrhosis, 2) Mass effect compressing central bile ducts, 3) Tumor invasion into bile ducts (icteric-type HCC), 4) Hemobilia (bleeding into biliary tree) ^[13].
• Differentiating Stone vs. Tumor: Crucial in clinical exams.

References

^[1] Senior notes: felixlai.md (Liver cirrhosis) ^[6] Senior notes: felixlai.md (Causes according to level of obstruction) ^[7] Senior notes: maxim.md (Differential diagnosis of obstructive jaundice) ^[8] Senior notes: felixlai.md (Recurrent pyogenic cholangitis) ^[9] Senior notes: felixlai.md (Primary sclerosing cholangitis) ^[10] Senior notes: felixlai.md (Courvoisier's law) ^[11] Senior notes: felixlai.md (Mirizzi syndrome) ^[12] Senior notes: maxim.md (DDx of post-operative jaundice) ^[13] Senior notes: felixlai.md (Hepatocellular carcinoma) ^[14] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p22) ^[15] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p32) ^[16] Lecture slides: Malignant biliary obstruction.pdf (p6)

Active Recall - Differential Diagnosis of Jaundice

1. A 65-year-old man presents with painless, deepening jaundice, pale stools, and dark urine over 4 weeks. On examination, he has a palpable, non-tender gallbladder. What is the most likely type and cause of his jaundice? Explain the pathophysiology of the physical finding.

Your answer

Grade

Show mark scheme

Type: Post-hepatic/Obstructive Jaundice. Likely Cause: Carcinoma of the head of the pancreas (or other periampullary malignancy). Pathophysiology of palpable gallbladder (Courvoisier's sign): The malignancy causes an acute, distal CBD obstruction. This back-pressurizes and distends a previously normal, compliant gallbladder. In contrast, gallstone disease causes chronic inflammation and fibrosis, rendering the gallbladder non-distensible.

2. A 30-year-old woman with known Ulcerative Colitis presents with pruritus and mild jaundice. Her LFTs show an ALP 3x ULN, GGT elevated, with only mild AST/ALT rise. What is the most likely diagnosis? Which imaging finding would be pathognomonic?

Your answer

Grade

Show mark scheme

Most likely diagnosis: Primary Sclerosing Cholangitis (PSC), given strong association with Ulcerative Colitis and a cholestatic LFT pattern. Pathognomonic imaging finding on MRCP/ERCP: Multiple focal strictures and dilations of the intra- and extra-hepatic bile ducts, creating a 'beaded' appearance.

3. List two causes of obstructive jaundice where the gallbladder might be palpable (i.e., exceptions to Courvoisier's Law), and briefly explain why for each.

Your answer

Grade

Show mark scheme

1. Mirizzi Syndrome: An impacted stone in the cystic duct causes inflammation/compression of the CHD, leading to jaundice. The associated acute cholecystitis or mucocele can cause gallbladder distention/palpability. 2. 'Double Impaction': A stone in the CBD causes jaundice, while a simultaneous stone in the cystic duct causes gallbladder outlet obstruction and mucocele/hydrops, leading to a palpable gallbladder.

4. A patient has jaundice with total bilirubin 150 µmol/L, direct bilirubin 140 µmol/L. Urinalysis is positive for bilirubin. Abdominal USG shows no biliary dilation. What are the two broad pathophysiological categories to consider? Name one specific example from each category.

Your answer

Grade

Show mark scheme

Categories: 1) Hepatic (Hepatocellular) Jaundice and 2) Early or Intrahepatic Obstructive (Cholestatic) Jaundice. Examples: 1) Viral Hepatitis (Hepatic). 2) Primary Biliary Cholangitis (PBC) or drug-induced cholestasis (Intrahepatic Obstructive).

5. What is the fundamental pathophysiological difference between the jaundice caused by acute viral hepatitis and that caused by a common bile duct stone? Refer to bilirubin metabolism.

Your answer

Grade

Show mark scheme

Viral Hepatitis (Hepatic): Hepatocyte inflammation and necrosis impair ALL phases of bilirubin metabolism (uptake, conjugation, excretion), leading to a mixed hyperbilirubinemia with high transaminases. CBD Stone (Obstructive): Mechanical blockage prevents the excretion of already conjugated bilirubin from the liver into the gut. This causes a pure conjugated hyperbilirubinemia, backed-up bile in the liver (cholestasis), and elevated ALP/GGT.

6. Why does a patient with hemolytic jaundice (e.g., from G6PD deficiency) typically have normal-colored stools and urine that is not dark (bilirubin-negative) but may have increased urobilinogen?

Your answer

Grade

Show mark scheme

In hemolysis, the excess bilirubin is unconjugated (lipid-soluble, albumin-bound). It cannot be filtered by the kidneys, so no bilirubinuria (normal-colored urine). The liver conjugates and excretes the increased load as best it can, leading to MORE conjugated bilirubin reaching the intestine. This produces MORE urobilinogen, some of which is reabsorbed and excreted in urine (increased urine urobilinogen) and the rest is excreted as stool pigment (normal or dark stools).

Diagnostic Criteria, Algorithm, and Investigations for Jaundice

The diagnostic approach to jaundice is a classic example of clinical reasoning: start with non-invasive, cheap, and informative tests to categorize the problem, then proceed to more targeted investigations.

Diagnostic Approach: History and Physical Examination

Before ordering tests, the history and exam provide critical clues that direct the entire workup.

• History: Focus on the onset (acute vs. chronic), associated symptoms (pain, fever, pruritus, weight loss), stool and urine color, drug history, alcohol use, travel, and personal/family history of liver or hematological disease. The key is to differentiate medical (pre-hepatic/hepatic) from surgical (obstructive) causes ^[17].
• Physical Examination:
  • Jaundice, Stigmata of chronic liver disease, Pruritus, Courvoisier’s law, Troisier’s sign (Virchow’s node), Hepatomegaly, Sister Joseph nodule, Ascites ^[18].
  • Courvoisier's Law is a cornerstone: a palpable, non-tender gallbladder in a jaundiced patient suggests malignant obstruction (e.g., pancreatic head cancer) rather than gallstones. Why? Chronic gallstone inflammation causes a fibrotic, non-distensible gallbladder. Acute malignant obstruction distends a previously normal gallbladder ^[10][19].
  • Look for signs of chronic liver disease (spider nevi, palmar erythema, ascites) and clues to malignancy (cachexia, Virchow's node).

Diagnostic Algorithm

The following algorithm synthesizes a logical, stepwise approach to diagnosing jaundice, integrating history, lab findings, and imaging.

Investigation Modalities: Key Findings and Interpretation

1. Blood Tests (First Line)

• Complete Blood Count (CBC):
  • Leukocytosis: Suggests infection (e.g., acute cholangitis).
  • Anemia: May be due to chronic disease, hemolysis, or bleeding from esophageal varices.
  • Thrombocytopenia: Could indicate hypersplenism from portal hypertension (cirrhosis) or consumptive coagulopathy.
• Liver Function Tests (LFTs): The pattern is everything.
  • Bilirubin Fractionation: Direct (conjugated) vs. Indirect (unconjugated). Conjugated hyperbilirubinemia implies a hepatic or post-hepatic problem.
  • Transaminases (AST, ALT): Markers of hepatocellular injury. Very high levels (>1000 U/L) suggest acute viral hepatitis, ischemic hepatitis, or toxin-induced injury. An AST:ALT ratio >2:1 is suggestive of alcoholic liver disease.
  • Alkaline Phosphatase (ALP) & Gamma-Glutamyl Transferase (GGT): Markers of cholestasis (impaired bile flow). A disproportionate elevation of ALP and GGT relative to AST/ALT points to an obstructive or infiltrative process. GGT confirms the hepatic origin of an elevated ALP.
  • Albumin & Prothrombin Time (PT/INR): Markers of hepatic synthetic function. Low albumin (long half-life) suggests chronic liver disease. Prolonged PT that corrects with Vitamin K points to malabsorption due to obstructive jaundice; if it doesn't correct, it indicates significant hepatocellular failure.
• Viral Serology: HBsAg, Anti-HCV, etc. Essential in Hong Kong given HBV endemicity ^[1].
• Inflammatory Markers (CRP, ESR): Elevated in infective/inflammatory conditions (cholangitis, autoimmune hepatitis).
• Tumor Markers: Never diagnostic on their own, used in conjunction with imaging.
  • CA 19-9: Associated with pancreatic, biliary, and gastric cancers. Also elevated in benign biliary obstruction (e.g., cholangitis, stones) and cholestasis, limiting its specificity ^[20][21].
  • AFP (Alpha-fetoprotein): Marker for Hepatocellular Carcinoma (HCC). Levels >400 ng/mL are highly suggestive in the right clinical context. Also elevated in germ cell tumors and active liver regeneration (e.g., hepatitis).
  • CEA (Carcinoembryonic Antigen): Raised in colorectal, gastric, pancreatic, and lung cancers. Non-specific.
• Autoantibodies:
  • Anti-Mitochondrial Antibody (AMA): >95% specific for Primary Biliary Cholangitis (PBC).
  • Anti-Nuclear Antibody (ANA), Anti-Smooth Muscle Antibody (ASMA): Seen in Autoimmune Hepatitis.
  • p-ANCA: Can be positive in Primary Sclerosing Cholangitis (PSC).

2. Imaging Modalities

• Ultrasonography (USG) Abdomen: The First and Most Important Imaging Test.
  • Why first? It's non-invasive, cheap, has no radiation, and answers the critical question: Are the bile ducts dilated?
  • Key Findings:
    • Dilated Intrahepatic and/or Extrahepatic Bile Ducts: Confirms obstructive (post-hepatic) jaundice. The level of dilation (intrahepatic only vs. both) helps localize the obstruction.
    • CBD Diameter: >8mm is generally considered dilated (allow 1mm per decade after age 50). A normal CBD on USG does not completely rule out obstruction (especially distal CBD stones hidden by bowel gas).
    • Cause: May visualize gallstones (in gallbladder or CBD), a mass in the pancreas or liver, or lymphadenopathy.
    • Liver Parenchyma: Can show signs of cirrhosis, fatty liver, or mass lesions.
• Computed Tomography (CT) Abdomen with Contrast:
  • Role: Excellent for staging malignancies (pancreatic cancer, cholangiocarcinoma) and assessing vascular involvement. Better than USG for visualizing the pancreas and retroperitoneum.
  • Key Findings for Pancreatic Cancer: Hypoattenuating pancreatic mass, double-duct sign (dilated CBD and pancreatic duct), and assessment of resectability (encasement of SMA, SMV, etc.) ^[23].
• Magnetic Resonance Cholangiopancreatography (MRCP):
  • Role: The best non-invasive test to visualize the biliary and pancreatic ductal anatomy. It has largely replaced diagnostic ERCP. It can show stones, strictures, and masses without the risk of pancreatitis.
  • Key Findings: Filling defects (stones), focal strictures with proximal dilation (tumor, PSC), and the "beaded" appearance of PSC.
• Endoscopic Ultrasound (EUS):
  • Role: Combines endoscopy and ultrasound. Excellent for tissue acquisition (fine-needle aspiration/FNA) of pancreatic or periampullary masses and for detecting small CBD stones missed by USG.
• Endoscopic Retrograde Cholangiopancreatography (ERCP):
  • Role: Primarily therapeutic, not diagnostic. It is an invasive procedure with risks (pancreatitis, bleeding, perforation). Used when intervention is anticipated.
  • Indications: 1) To relieve obstruction (stone extraction, stent placement), 2) To obtain brushings/biopsy from a stricture, 3) When MRCP is equivocal and clinical suspicion for obstruction is high.
• Percutaneous Transhepatic Cholangiography (PTC) & Drainage (PTBD):
  • Role: Used when ERCP fails or is not possible (e.g., altered anatomy, previous gastric surgery) or for proximal/hilar obstructions (e.g., Klatskin tumor). A needle is passed through the skin into a dilated intrahepatic duct, contrast is injected (PTC), and a drain can be placed (PTBD) to decompress the system.

3. Liver Biopsy

• Role: Not routine. Used when the cause of hepatocellular or intrahepatic cholestatic jaundice remains unclear after exhaustive non-invasive testing (e.g., diagnosing autoimmune hepatitis, grading/staging NASH, confirming PBC or PSC when serology/MRCP is ambiguous).

Specific Diagnostic Criteria

• Acute Cholangitis (Tokyo Guidelines):
  • Suspected Diagnosis: A. Systemic Inflammation (Fever/Shivers OR lab evidence: ↑WBC, ↑CRP) AND B. Cholestasis (Jaundice OR abnormal LFTs: ↑ALP, GGT, AST, ALT).
  • Definite Diagnosis: Suspected diagnosis AND C. Imaging evidence of biliary dilation or an etiology (stone, stricture, stent) ^[26].
• Primary Biliary Cholangitis (PBC): Diagnosis requires 2 of 3: 1) ALP ≥ 1.5x ULN, 2) Positive AMA (≥1:40), 3) Liver biopsy showing non-suppurative destructive cholangitis ^[27].
• Primary Sclerosing Cholangitis (PSC): Diagnosis is based on cholangiographic findings (MRCP or ERCP) showing multifocal strictures and segmental dilatations of the intra- and/or extra-hepatic bile ducts, after excluding secondary causes (e.g., stones, surgery) ^[9].
• Hepatocellular Carcinoma (HCC): In patients with cirrhosis, a focal liver lesion >1 cm with typical imaging characteristics (arterial phase hyperenhancement and venous/delayed phase "washout" on multiphase CT or MRI) is diagnostic without the need for biopsy.

References

^[1] Senior notes: felixlai.md (Liver cirrhosis) ^[10] Senior notes: felixlai.md (Courvoisier's law) ^[17] Senior notes: maxim.md (Important questions in history taking) ^[18] Lecture slides: Malignant biliary obstruction.pdf (p6) ^[19] Senior notes: felixlai.md (Diagnosis - Courvoisier's law) ^[20] Senior notes: felixlai.md (CA 19-9) ^[21] Senior notes: maxim.md (Tumor markers) ^[22] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p4) ^[23] Senior notes: felixlai.md (CT findings in pancreatic cancer) ^[24] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p34) ^[25] Lecture slides: Malignant biliary obstruction.pdf (p10) ^[26] Senior notes: felixlai.md (Diagnostic criteria for acute cholangitis) ^[27] Senior notes: felixlai.md (Diagnostic criteria for PBC)

Active Recall - Diagnosis of Jaundice

1. What is the single most important initial imaging test for a patient with new-onset jaundice, and what is the critical question it must answer?

Your answer

Grade

Show mark scheme

Test: Abdominal Ultrasound (USG). Critical question: Are the intrahepatic and/or extrahepatic bile ducts dilated? This dichotomizes the workup into obstructive vs. non-obstructive causes.

2. A jaundiced patient has a prolonged Prothrombin Time (PT). How can you differentiate between a deficiency caused by obstructive jaundice versus severe hepatocellular failure?

Your answer

Grade

Show mark scheme

Administer parenteral (IV or IM) Vitamin K. If the PT corrects significantly (e.g., >30% improvement) within 24-48 hours, the cause is likely Vitamin K malabsorption from obstructive jaundice. If it does not correct, it indicates profound impairment of hepatic synthetic function (hepatocellular failure).

3. Describe the typical Liver Function Test (LFT) pattern for Obstructive Jaundice and explain the underlying pathophysiology for each component.

Your answer

Grade

Show mark scheme

Pattern: Markedly elevated Conjugated Bilirubin, Alkaline Phosphatase (ALP), and Gamma-Glutamyl Transferase (GGT) with only mild-moderate elevations in AST/ALT. Pathophysiology: Bilirubin: Conjugated bilirubin backs up into blood due to mechanical blockage. ALP/GGT: Induced in bile duct epithelial cells (cholangiocytes) in response to obstruction and retained bile acids. AST/ALT: Only mildly elevated from secondary hepatocyte irritation, not primary injury.

4. According to the Tokyo Guidelines, what three components are required to make a 'definite' diagnosis of acute cholangitis?

Your answer

Grade

Show mark scheme

1) Evidence of systemic inflammation (fever/chills OR raised WBC/CRP). 2) Evidence of cholestasis (jaundice OR abnormal LFTs: ↑ALP/GGT/AST/ALT). 3) Imaging evidence of biliary dilation OR a specific etiology (e.g., stone, stricture).

5. When is an ERCP indicated in the workup of jaundice? What are its primary advantages and risks compared to MRCP?

Your answer

Grade

Show mark scheme

Indication: When therapeutic intervention is anticipated (e.g., stone removal, stent placement for obstruction) or when tissue sampling from the bile duct is needed. Advantage: It is therapeutic. Risks: Invasive with risks of pancreatitis (3-5%), bleeding, perforation, and infection. MRCP is non-invasive, has no therapeutic capability, and is used primarily for diagnosis.

6. A 55-year-old woman with pruritus and jaundice has an ALP of 450 U/L (normal <120) and is positive for Anti-Mitochondrial Antibody (AMA) at a titer of 1:160. What is the most likely diagnosis, and what is the next best step to confirm it?

Your answer

Grade

Show mark scheme

Most likely diagnosis: Primary Biliary Cholangitis (PBC). Next step: A liver biopsy is not mandatory if AMA is positive and LFTs are cholestatic. The diagnosis can be made with 2 out of 3 criteria: cholestatic LFTs, positive AMA, and compatible histology. In this case, she already meets 2 criteria (ALP and AMA), so biopsy may be reserved for atypical cases or staging.

Management Algorithm and Treatment Modalities for Jaundice

The management of jaundice is entirely directed at treating its underlying cause. However, the approach to obstructive (surgical) jaundice involves specific, often urgent, interventions to relieve the blockage and treat complications like infection. The management of hepatic (medical) jaundice is primarily supportive and disease-specific.

The cornerstone of managing obstructive jaundice is biliary decompression – relieving the blockage to allow bile to flow. The method depends on the cause, level of obstruction, patient fitness, and whether the goal is curative or palliative.

General Management Principles (Supportive Care)

Before specific treatment, address the systemic effects of jaundice and cholestasis:

• Correct Coagulopathy: Administer parenteral Vitamin K (e.g., 10 mg IV/IM) to correct PT/INR prolonged due to malabsorption. Fresh Frozen Plasma (FFP) may be needed for urgent procedures.
• Manage Pruritus: Cholestyramine (bile acid sequestrant), antihistamines, or rifampicin.
• Nutritional Support: Fat-soluble vitamin (A, D, E, K) supplementation. Consider medium-chain triglycerides (MCTs) for steatorrhea as they are absorbed without bile salts.
• Renal Protection: Maintain hydration; obstructive jaundice predisposes to hepatorenal syndrome.

Management Algorithm for Obstructive Jaundice

The following algorithm outlines the decision-making pathway, from initial stabilization to definitive therapy.

Treatment Modalities for Specific Conditions

1. Acute Cholangitis

A life-threatening infection requiring urgent intervention. Remember the mnemonic RAD: Resuscitation, Antibiotics, Drainage ^[28].

• Resuscitation: IV fluids, monitor vitals, correct electrolytes.
• Antibiotics: IV broad-spectrum antibiotics covering enteric Gram-negatives and anaerobes (e.g., piperacillin-tazobactam or cefuroxime + metronidazole) ^[29].
• Biliary Drainage (Decompression): Required urgently if no response to antibiotics within 12-24 hours or immediately if Reynold's pentad (shock, altered mentation) is present.
  • First line: ERCP with biliary stenting (and/or sphincterotomy/stone extraction if feasible). This relieves pressure, drains infected bile, and allows antibiotics to penetrate ^[30].
  • Alternatives: PTBD (if ERCP fails, contraindicated, or for proximal obstructions) or, rarely, surgical common bile duct exploration (ECBD).
• Definitive Treatment: Once sepsis is controlled, treat the underlying cause (e.g., cholecystectomy for gallstones).

2. Choledocholithiasis (CBD Stones)

• Symptomatic or Complicated Stones (causing jaundice, cholangitis, pancreatitis):
  • ERCP with Sphincterotomy and Stone Extraction is the standard first-line therapy ^[31]. Techniques include balloon trawl, basket extraction, or mechanical lithotripsy for large stones.
  • Timing: For concomitant acute biliary pancreatitis, ERCP is indicated within 24-72 hours if there is persistent biliary obstruction or cholangitis.
  • Subsequent Cholecystectomy: Laparoscopic cholecystectomy should be performed during the same admission or within 2-4 weeks after ERCP to prevent recurrent biliary events.
• Asymptomatic CBD Stones: Management is debated; ERCP may be considered if stones are large (>1cm) or if the patient is undergoing cholecystectomy.

3. Malignant Biliary Obstruction (MBO)

Management hinges on resectability (curative intent) vs. unresectability (palliative intent) ^[32].

A. Curative-Intent Treatment (Resectable Disease)

• Pre-operative Preparation:
  • Pre-operative Biliary Drainage is controversial. Traditionally used to lower bilirubin (< 50 µmol/L) to reduce surgical risks (coagulopathy, renal impairment, infection). However, it can increase complications (stent occlusion, cholangitis). Current guidelines suggest avoiding routine drainage if surgery can be performed within 1-2 weeks. In practice (e.g., QMH), drainage is often done due to surgical waiting times ^[33].
  • Nutritional support and correction of coagulopathy.
• Surgical Resection:
  • Carcinoma of Head of Pancreas/Periampullary: Pancreaticoduodenectomy (Whipple procedure). Pylorus-preserving (PPPD) is often preferred.
  • Cholangiocarcinoma:
    • Perihilar (Klatskin): Major hepatectomy (often extended hepatectomy) + bile duct resection + caudate lobectomy + Roux-en-Y Hepaticojejunostomy.
    • Distal CBD: Pancreaticoduodenectomy (similar to pancreatic head cancer).
    • Intrahepatic: Partial hepatectomy.
  • Gallbladder Carcinoma: Radical cholecystectomy (cholecystectomy + wedge resection of liver segments IVb/V + portal lymphadenectomy).
• Adjuvant Therapy: Chemotherapy (e.g., Gemcitabine + Capecitabine for pancreas; Capecitabine for biliary) is standard post-resection to improve survival.

B. Palliative-Intent Treatment (Unresectable Disease) Goals: Relieve obstruction, treat sepsis, control pain ^[34].

• Biliary Decompression:
  • Endoscopic Stenting (ERCP): First-line for distal CBD obstructions. Self-expandable metallic stents (SEMS) are preferred over plastic for longer patency if life expectancy >3-4 months.
  • Percutaneous Transhepatic Biliary Drainage (PTBD): Indicated for proximal/hilar obstructions, or when ERCP fails or is contraindicated (e.g., altered anatomy like Roux-en-Y, gastric outlet obstruction) ^[35].
• Duodenal Stenting or Gastrojejunostomy: For malignant gastric outlet obstruction.
• Pain Control: Opioids, celiac plexus neurolysis (EUS or CT-guided).
• Systemic Therapy: Chemotherapy (e.g., FOLFIRINOX, Gemcitabine-based regimens) for pancreatic/biliary cancers.

4. Recurrent Pyogenic Cholangitis (RPC - "Hong Kong Disease")

Management is challenging due to intrahepatic stones and strictures.

• Acute Episode: Managed as acute cholangitis (RAD). PTBD is often more effective than ERCP for draining the frequently affected intrahepatic ducts.
• Definitive/Preventive Therapy: Aims to break the cycle of stasis-infection-stone formation.
  • Endoscopic/Interventional: Repeated ERCP sessions for stone clearance and stricture dilation.
  • Surgical: Hepatectomy of the atrophic, stone-laden liver segment (often left lateral section) + Roux-en-Y Hepaticojejunostomy to provide free biliary drainage. This is indicated for localized disease, failed non-operative management, or suspicion of cholangiocarcinoma ^[37].

5. Choledochal Cysts

Complete surgical excision is mandatory due to high risk of cholangiocarcinoma.

• Procedure: Complete cyst excision + Roux-en-Y Hepaticojejunostomy.
• Why excision? Removes the premalignant epithelium. Internal drainage procedures alone (e.g., cyst-enterostomy) are contraindicated as they leave the cancer risk.
• Type V (Caroli's Disease): If unilateral, hemihepatectomy. If diffuse, may require liver transplantation.

6. Primary Sclerosing Cholangitis (PSC) & Primary Biliary Cholangitis (PBC)

• PSC: No cure except liver transplantation for end-stage disease. Dominant strictures causing obstruction/cholangitis may be treated with endoscopic balloon dilation ± stenting. Ursodeoxycholic acid (UDCA) is used but of limited proven benefit.
• PBC: First-line treatment is UDCA 13-15 mg/kg/day, which slows disease progression. Obeticholic acid is second-line. Liver transplantation for end-stage disease.

References

^[28] Senior notes: maxim.md (Acute management of cholangitis - RAD) ^[29] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (p13) ^[30] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (p14) ^[31] Senior notes: maxim.md (Choledocholithiasis management) ^[32] Lecture slides: Malignant biliary obstruction.pdf (p18) ^[33] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p67) ^[34] Lecture slides: Malignant biliary obstruction.pdf (p30) ^[35] Senior notes: felixlai.md (PTBD indications) ^[36] Senior notes: felixlai.md (ERCP contraindications) ^[37] Senior notes: felixlai.md (RPC surgical treatment)

Active Recall - Management of Jaundice

1. What are the three key components of the 'RAD' approach to managing acute cholangitis, and why is drainage so critical?

Your answer

Grade

Show mark scheme

R: Resuscitation (IV fluids). A: Antibiotics (IV broad-spectrum). D: Drainage (urgent biliary decompression via ERCP/PTBD). Drainage is critical because antibiotics cannot effectively penetrate the obstructed, infected biliary tree. Relieving the obstruction drains pus, lowers intrabiliary pressure, and restores antibiotic penetration.

2. A patient with a distal CBD stone causing obstructive jaundice undergoes ERCP with sphincterotomy and stone extraction. What is the subsequent definitive management, and why is it necessary?

Your answer

Grade

Show mark scheme

Subsequent definitive management is laparoscopic cholecystectomy. It is necessary because the gallbladder is the source of the stones. Leaving it in situ carries a high risk of recurrent biliary events (new stones, cholangitis, pancreatitis).

3. List two specific clinical scenarios where Percutaneous Transhepatic Biliary Drainage (PTBD) would be preferred over ERCP for biliary decompression.

Your answer

Grade

Show mark scheme

1. Proximal/Hilar malignant obstruction (e.g., Klatskin tumor), where endoscopic access and stenting are difficult. 2. Altered upper GI anatomy (e.g., prior Roux-en-Y gastric bypass or Billroth II gastrectomy) that prevents endoscopic access to the ampulla.

4. What is the main argument AGAINST routine pre-operative biliary drainage in a patient with resectable pancreatic head cancer and jaundice? What is a practical reason it is often done in Hong Kong?

Your answer

Grade

Show mark scheme

Argument against: Pre-operative drainage does not reduce surgical morbidity/mortality and may increase complications (stent-related cholangitis, pancreatitis). Practical reason in HK (e.g., QMH): Long waiting times for major surgery (e.g., 6-8 weeks for Whipple) make the risk of developing cholangitis while waiting unacceptably high without drainage.

5. Why is complete surgical excision, rather than simple internal drainage, the mandatory treatment for a Type I choledochal cyst?

Your answer

Grade

Show mark scheme

Because the cyst wall has a premalignant epithelium with a lifetime risk of cholangiocarcinoma of up to 30%. Excision removes this risk. Internal drainage procedures (e.g., cyst-enterostomy) leave the cyst in situ and do not eliminate the cancer risk.

6. A patient with known PSC develops worsening jaundice and cholangitis. MRCP shows a dominant stricture in the common hepatic duct. What is the appropriate endoscopic intervention?

Your answer

Grade

Show mark scheme

Endoscopic balloon dilation of the dominant stricture, with possible short-term stenting if necessary. The goal is to relieve the obstruction and treat cholangitis. Long-term stenting is avoided due to risks of occlusion and infection.

Complications of Jaundice

Jaundice itself is a sign, not a disease, so its "complications" are really the consequences of the underlying disorder and the physiological disturbances caused by the accumulation of bilirubin and, in the case of cholestasis, retained bile constituents. Understanding these complications is crucial because they often dictate the urgency and goals of management.

1. Complications of Severe Unconjugated Hyperbilirubinemia (Primarily in Neonates)

This is a critical area in pediatrics. Unconjugated bilirubin (UCB) is lipid-soluble and can cross the blood-brain barrier, especially when it is unbound to albumin (free bilirubin).

• Acute Bilirubin Encephalopathy (ABE): The acute, potentially reversible neurotoxic effects of high UCB.
  • Pathophysiology: Free UCB enters neurons, disrupts mitochondrial function, and induces apoptosis and necrosis. Risk is highest in neonates with immature blood-brain barriers, hemolysis, acidosis, or sepsis.
  • Clinical Phases:
    • Early (1-2 days): Lethargy, hypotonia, poor suck.
    • Intermediate (mid-first week): Hypertonia (especially of extensor muscles), fever, retrocollis/opisthotonos (backward arching).
    • Advanced (after first week): Pronounced hypertonia, high-pitched cry, seizures, coma.
• Kernicterus: The chronic, permanent neurological sequelae of severe, untreated ABE.
  • Pathophysiology: Permanent neuronal injury and bilirubin staining of the basal ganglia, hippocampus, and brainstem nuclei.
  • Clinical Features: Choreoathetoid cerebral palsy, sensorineural hearing loss, upward gaze palsy, dental enamel dysplasia, and intellectual deficits.

2. Systemic Complications of Cholestasis (Conjugated Hyperbilirubinemia)

When bile flow is impaired, substances normally excreted in bile accumulate systemically, causing a cascade of problems.

• Pruritus (Itching): One of the most debilitating symptoms.
  • Pathophysiology: Not fully understood, but likely mediated by bile salts accumulating in the skin and activating itch receptors (e.g., TGR5, MRGPRX4). Other theories involve endogenous opioids and lysophosphatidic acid.
• Malabsorption and Fat-Soluble Vitamin (A, D, E, K) Deficiency:
  • Pathophysiology: Bile acids are essential for emulsifying dietary fats. Their absence leads to steatorrhea (fatty, foul-smelling, pale stools). The fat-soluble vitamins (A, D, E, K) are absorbed with fats, so their absorption is also impaired.
  • Specific Deficiencies:
    • Vitamin K: Leads to a coagulopathy, prolonging PT/INR. This is a classic finding in obstructive jaundice and can be corrected with parenteral Vitamin K.
    • Vitamin D & Calcium: Contribute to hepatic osteodystrophy (osteopenia, osteoporosis, osteomalacia). The mechanism is multifactorial: malabsorption, direct toxic effects of retained substances on osteoblasts, and metabolic disturbances.
    • Vitamin A: Can cause night blindness and dry eyes (xerophthalmia).
• Hyperlipidemia and Xanthomas:
  • Pathophysiology: Impaired excretion of cholesterol in bile leads to elevated serum cholesterol. Lipoprotein-X, an abnormal lipoprotein, also accumulates. This can lead to cholesterol deposition in skin (xanthelasma, tuberous xanthomas) and tendons.
• Coagulopathy: As mentioned, from Vitamin K deficiency. In advanced liver disease, there is also impaired hepatic synthesis of clotting factors (II, VII, IX, X), which is not corrected by Vitamin K.
• Endotoxemia and Immune Dysfunction:
  • Pathophysiology: The liver's Kupffer cells (resident macrophages) normally clear gut-derived endotoxins (bacterial lipopolysaccharides). In obstructive jaundice and liver failure, this function is impaired, leading to systemic endotoxemia. This, combined with impaired cell-mediated immunity and reticuloendothelial function, predisposes to bacterial infections, sepsis, and poor wound healing ^[38][39].
• Renal Dysfunction (Hepatorenal Syndrome - HRS):
  • Pathophysiology: Advanced liver disease and portal hypertension lead to profound splanchnic vasodilation, reducing effective arterial blood volume. This triggers intense renal vasoconstriction, leading to acute kidney injury (functional, not structural). Obstructive jaundice itself also increases the risk of acute kidney injury.
• Cirrhosis and Portal Hypertension: Chronic cholestasis (e.g., from PBC, PSC, chronic obstruction) leads to progressive hepatic fibrosis, nodular regeneration, and ultimately cirrhosis. This brings its own set of life-threatening complications:
  • Variceal Hemorrhage: From portal hypertensive gastropathy and esophageal/gastric varices.
  • Ascites and Spontaneous Bacterial Peritonitis (SBP).
  • Hepatic Encephalopathy.

3. Disease-Specific Complications

• Acute Cholangitis:
  • Can rapidly progress from Charcot's triad (fever, pain, jaundice) to Reynolds' pentad (+ shock and altered mental status), indicating severe sepsis or septic shock.
  • Liver abscess formation.
  • Multi-organ failure (renal, respiratory, circulatory).
• Recurrent Pyogenic Cholangitis (RPC):
  • Secondary Biliary Cirrhosis from chronic obstruction and recurrent infection.
  • Cholangiocarcinoma – a feared long-term complication due to chronic inflammation and epithelial injury ^[42].
  • Liver abscess, pancreatitis, biliary fistula formation (e.g., to duodenum or abdominal wall).
• Primary Sclerosing Cholangitis (PSC):
  • Dominant strictures causing worsening obstruction and cholangitis.
  • Very high lifetime risk of Cholangiocarcinoma (up to 10-15%). Screening with MRI/MRCP and CA19-9 is recommended.
  • Progression to cirrhosis and liver failure.
• Primary Biliary Cholangitis (PBC):
  • Hepatic osteodystrophy is particularly prominent.
  • Hyperlipidemia (but interestingly, this does not seem to increase atherosclerotic risk significantly).
  • Progression to cirrhosis and increased risk of Hepatocellular Carcinoma (HCC), especially in advanced disease.
• Malignant Biliary Obstruction (e.g., Pancreatic Cancer, Cholangiocarcinoma):
  • Cancer cachexia: Severe weight loss and muscle wasting from systemic inflammation and metabolic dysregulation.
  • Duodenal/Gastric Outlet Obstruction: From direct tumor invasion.
  • Pain: From tumor invasion of the retroperitoneal nerves (e.g., celiac plexus).
  • Metastatic disease (liver, peritoneum, lung).
• Hepatocellular Carcinoma (HCC):
  • Tumor rupture leading to life-threatening hemoperitoneum.
  • Obstructive jaundice from tumor invasion of bile ducts (icteric-type HCC) or compression.
  • Paraneoplastic syndromes (e.g., hypercalcemia, polycythemia, hypoglycemia).

4. Complications of Diagnostic and Therapeutic Interventions

• Endoscopic Retrograde Cholangiopancreatography (ERCP):
  • Acute Pancreatitis (3-5%): The most common major complication. Why? Trauma to the pancreatic duct orifice or hydrostatic injury from contrast injection.
  • Bleeding (1-2%): Post-sphincterotomy.
  • Perforation (< 1%): Duodenal or bile duct.
  • Cholangitis/Cholecystitis: From incomplete drainage or introducing infection.
  • Sedation-related complications (cardiopulmonary).
• Percutaneous Transhepatic Biliary Drainage (PTBD):
  • Hemorrhage (5%): Laceration of hepatic artery or portal vein during needle pass. Can be catastrophic.
  • Bile Leak and Peritonitis.
  • Catheter dislodgement or occlusion.
  • Pleural complications (pneumothorax, hemothorax) if a high puncture is made.
• Pre-operative Biliary Drainage (Stenting/PTBD):
  • While intended to reduce surgical risk, it can increase overall complication rates due to stent-related issues: cholangitis (26%), blocked stent (15%), pancreatitis (7%) ^[43].
• Major Hepatobiliary Surgery (e.g., Whipple, Hepatectomy):
  • Anastomotic Leak: Pancreaticojejunostomy leak is the most feared and common major complication after Whipple surgery, leading to intra-abdominal abscess, sepsis, and hemorrhage.
  • Delayed Gastric Emptying.
  • Post-hepatectomy Liver Failure: The "50-50 rule" (Bilirubin >50 µmol/L and INR >1.7 on post-op day 5) predicts high mortality.
  • Bile Leak.
  • Hemorrhage.
  • Infection.

References

^[38] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p64) ^[39] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf (p66) ^[40] Lecture slides: Malignant biliary obstruction.pdf (p24) ^[41] Lecture slides: Malignant biliary obstruction.pdf (p29) ^[42] Senior notes: felixlai.md (Complications of RPC) ^[43] Lecture slides: Malignant biliary obstruction.pdf (p26)

Active Recall - Complications of Jaundice

1. Why does a patient with prolonged obstructive jaundice develop a prolonged PT/INR? Describe two distinct pathophysiological mechanisms and a simple test to differentiate between them.

Your answer

Grade

Show mark scheme

Mechanism 1: Malabsorption of fat-soluble vitamin K due to lack of bile in the gut, leading to deficient synthesis of vitamin K-dependent clotting factors (II, VII, IX, X). Mechanism 2: Impaired hepatic synthetic function from concomitant liver damage, leading to reduced production of all clotting factors. Test: Administer parenteral Vitamin K. If PT corrects significantly (>30% improvement), the cause is primarily vitamin K deficiency. If it does not correct, it indicates significant hepatocellular failure.

2. What is hepatic osteodystrophy, and why is it a common complication in patients with chronic cholestatic liver diseases like PBC and PSC?

Your answer

Grade

Show mark scheme

Hepatic osteodystrophy refers to metabolic bone disease (osteopenia, osteoporosis, osteomalacia) in chronic liver disease. In cholestasis, it results from: 1) Malabsorption of Vitamin D and calcium due to steatorrhea. 2) Direct inhibitory effects of retained substances (e.g., bilirubin, bile acids) on osteoblast function. 3) Potential contributions from hormonal imbalances and chronic inflammation.

3. A neonate with severe unconjugated hyperbilirubinemia develops opisthotonos (backward arching of the neck and trunk). What is this clinical sign indicative of, and what is the underlying pathophysiological process in the brain?

Your answer

Grade

Show mark scheme

This is indicative of the intermediate phase of Acute Bilirubin Encephalopathy (ABE). The underlying process is neurotoxicity from free, unconjugated bilirubin crossing the blood-brain barrier, entering neurons (particularly in the basal ganglia and brainstem), disrupting mitochondrial function, and causing neuronal injury (apoptosis/necrosis).

4. List three major complications specific to Recurrent Pyogenic Cholangitis (RPC) that result from its chronic, recurrent nature.

Your answer

Grade

Show mark scheme

1. Secondary Biliary Cirrhosis (from chronic obstruction and inflammation). 2. Cholangiocarcinoma (from chronic epithelial injury and inflammation). 3. Liver abscess formation (from recurrent bacterial infection in obstructed ducts).

5. Why is a patient with malignant biliary obstruction at high risk for post-operative infections and poor wound healing, even before surgery? Refer to specific immune dysfunctions.

Your answer

Grade

Show mark scheme

6. What is the most common major complication of an ERCP procedure, and what is its typical pathophysiological mechanism?

Your answer

Grade

Show mark scheme

The most common major complication is Acute Pancreatitis (3-5%). Mechanism: Trauma or edema at the pancreatic duct orifice (often from sphincterotomy or cannulation attempts) and/or hydrostatic injury from contrast injection into the pancreatic duct, leading to premature activation of pancreatic enzymes and autodigestion.